Search

Displaying results 3441 - 3450 of 4588 in total
  1. Drug

    Fasedienol

    go.drugbank.com/drugs/DB04968
    Investigational

    PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder).

  2. Drug

    AP5346

    go.drugbank.com/drugs/DB04992
    Investigational

    It is being pursued by Access Pharmaceuticals, Inc.

  3. Drug

    ChAd-triCoV/Mac

    go.drugbank.com/drugs/DB24997
    Investigational

    ChAd-triCoV/Mac is under investigation in clinical trial NCT06381739 (A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol).

  4. Drug

    Sofalcone

    go.drugbank.com/drugs/DB05197
    Experimental

    Sofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. on adherence, production of vacuolating toxin (VT), and induction of interleukin-8 (IL-8) secretion by

  5. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    It is developed by MedImmune for the treatment of Allergic Rhinitis.

  6. Drug

    Ademetionine

    go.drugbank.com/drugs/DB00118
    ApprovedInvestigationalNutraceutical

    Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)

  7. Drug

    Fosamprenavir

    go.drugbank.com/drugs/DB01319
    ApprovedInvestigational

    Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.

  8. Drug

    Voglibose

    go.drugbank.com/drugs/DB04878
    Investigational

    It is made in India by Ranbaxy Labs and sold under the trade name Volix.

  9. Drug

    Cry5B

    go.drugbank.com/drugs/DB17783
    Experimental

    Cry5B is a pore-forming crystal protein produced by and derived from the soil bacterium _Bacillus thuringiensis_.

  10. Drug

    2X-121

    go.drugbank.com/drugs/DB16063
    Investigational

    2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the